New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
05:06 EDTOSIROsiris Therapeutics successfully defends key stem cell patent challenge
Osiris Therapeutics announced the successful conclusion of a patent challenge in Australia by an opponent whose identity under Australian law was not disclosed. The patent at issue covers the administration of mesenchymal stem cells, or MSCs, including Prochymal, for the treatment of inflammatory conditions involving the gastrointestinal tract, including Crohn's disease and ulcerative colitis. As acknowledged in the Australian Official Journal of Patents Supplement, all claims to the patent will be maintained in full. The claims specifically include the use of allogeneic MSCs, an attribute central to making an off-the-shelf MSC product possible.
News For OSIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
07:25 EDTOSIROsiris price target lowered to $4 from $8 at Brean Capital
Subscribe for More Information
February 3, 2016
16:34 EDTOSIROsiris appoints Chief Business OfficerDwayne Montgomery as Interim CEO
Subscribe for More Information
February 2, 2016
11:03 EDTOSIROsiris price target lowered to $18.50 from $28 at Piper Jaffray
Subscribe for More Information
08:01 EDTOSIROsiris announces 100% Medicare coverage for Grafix
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use